We are live on ! Find out more

NAGE

Niagen Bioscience

NAGE

Market cap $241M

3.04 USD

0.00

0%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

3.04

0.00

0%

1 day

0%

5 days

-3.8%

1 month

0.66%

3 months

-13.64%

6 months

-36.67%

Year to date

-51.36%

1 year

-68.6%

5 years

-56.32%

10 years

-8.71%

About: Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Employees: 117

Consumer Staples Packaged Foods

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 5.3%

Neutral 94.7%

Negative 0%

Niagen Bioscience to Present at Canaccord Genuity's Well Summit

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity's Well Summit, taking place from September 28 to 30, 2026, in New York. Mr. Fried is scheduled to participate in the Aging on Trial: Peptides, Hormones, and the Line Between Brea.

Niagen Bioscience to Present at Canaccord Genuity's Well Summit

Niagen Bioscience to Present at Longevity Investors Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.Niagen Bioscience CEO, Rob Fried, will participate in the Longevity Goes Mainstream: The Investment Case for Consumer Health Panel on Wednesday, September 16.

Niagen Bioscience to Present at Longevity Investors Conference

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San Francisco, CA.Nasdaq is partnering with LD Micro to host 25 curated public companies, each delivering a 15-minute presentation to a room of institutional investors within the Nas.

Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam's Club retail locations and online at www.gnc.com and www.samsclub.com. “Expanding Tru Niagen across GNC and Sam's Club strengthens our retail footprint and puts the category-l.

Niagen Bioscience Expands Tru Niagen® Retail Footprint with GNC and Sam's Club

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL. IDEAS Conferences offer independent regional venues for top-tier companies to present their investment merits to instrumental audiences of investme.

Niagen Bioscience to Present at the 17th Annual Midwest IDEAS Investor Conference

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Walmart.com. The launch expands access to Tru Niagen through one of the country's largest digital retail platforms, providing more consumers with a convenient way to purchase a clinically proven,.

Niagen Bioscience Launches Tru Niagen on Walmart.com, Expanding Access and Diversifying Its E-commerce Marketplace Presence

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Niagen Bioscience, Inc. (NAGE) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience (NAGE) came out with quarterly earnings of $0.01 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.04 per share a year ago.

Niagen Bioscience (NAGE) Meets Q2 Earnings Estimates

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026. Second Quarter 2026 Financial and Business Highlights Total net sales of $29.8 million, including $24.2 million from Tru Niagen®. Direct to consumer sales on the Company's website grew by 23% year-over-year. Gross margin of 64.8%, reflecting continued strength in business mix. Net income of $1.0 million, with basic and diluted earnings per.

Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N.

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

See News Rankings

Price charts implemented using Lightweight Charts™